| abstract |
The present invention relates to a binding agent comprising peptides capable of binding to myostatin and inhibiting its activity. In one embodiment, the binding agent comprises one or more myostatin-binding peptides attached directly or indirectly to one or more vehicles, such as a polymer or Fc domain. The binding agent of the present invention increases the amount of fat in the animal and decreases the fat to muscle ratio when administered to an animal. Therapeutic compositions containing the binding agents of the present invention are useful in treating muscle wasting disorders, and other metabolic disorders including diabetes and obesity. |